IDEXX Laboratories, Inc. (IDXX) director Lawrence D. Kingsley reported an option exercise and share sale on September 4, 2026. He exercised a non-qualified stock option for 2,203 shares of common stock at an exercise price of $114.17 per share and sold all 2,203 shares at a weighted average price of $532.0826 per share, with sale prices ranging from $531.88 to $532.14. The option, which vested in one installment on May 3, 2017, now has no remaining derivative shares reported after the exercise, and no Rule 10b5-1 trading plan is reported.
IDEXX LABORATORIES, INC. (IDXX) received a Rule 144 notice from director Lawrence D. Kingsley covering a proposed sale of company common stock. The notice lists 2,203 shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,172,178.19 and 78,781,116 shares of this class outstanding.
The shares to be sold were acquired from the issuer through a stock option exercise, with acquisition and payment by cash both dated September 4, 2026. The planned sale date is also listed as September 4, 2026, and the common stock is identified as trading on NASDAQ.
IDEXX LABORATORIES INC /DE (IDXX) reported insider equity activity by Andrew Emerson, EVP, CFO and Treasurer. On August 20, 2026, he exercised an Incentive Stock Option to acquire 265 shares of common stock at an exercise price of $178.26 per share, reducing the option balance to 925 options expiring February 13, 2028. In connection with this exercise, 86 shares of common stock were delivered or withheld to cover the exercise price or tax liability. The filing notes that his common stock holdings include 20 shares purchased under the Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026.
IDEXX Laboratories, Inc. reported Q2 2026 total revenue of $1,216,585 (in thousands), up from $1,109,457, with net income of $338,412 and diluted EPS of $4.27, both higher than a year earlier. For the first six months, revenue reached $2,357,405 (in thousands) and net income $616,858.
Growth was led by the Companion Animal Group, with Q2 segment revenue of $1,118,236 (in thousands); Water and LPD also increased. Operating cash flow for the six months rose to $613,410 (in thousands), funding $703,732 (in thousands) of share repurchases while cash increased to $196,933 (in thousands).
The balance sheet shows total assets of $3,442,335 (in thousands) and borrowings of $519,000 (in thousands) under a $1.25 billion Credit Facility, with covenant compliance and $729.2 million of remaining availability. Customer commitment arrangements support estimated future revenues of approximately $5.3 billion over several years.
IDEXX Laboratories reported strong second‑quarter 2026 results, with revenue of $1,217 million, up 10% as reported and 9% organic versus the prior year. Diluted EPS was $4.27, an 18% increase, while comparable EPS grew 15% to $4.07. Gross margin reached 64.0% and operating margin 35.0%, both expanding 140 basis points year over year.
Growth was broad-based: Companion Animal Group revenue rose 9% as reported and 8.7% organic, driven by 11.0% reported and 10.3% organic growth in CAG Diagnostics recurring revenue, while Water revenue increased 14.8% reported and 13.0% organic and LPD revenue grew 10.8% reported and 9.0% organic.
The company raised its 2026 outlook, guiding revenue to $4,700–$4,745 million with 9.1%–10.3% reported growth and 8.5%–9.7% organic growth. It now expects operating margin of 32.3%–32.5% and EPS of $14.69–$14.94, implying 12%–14% reported and 13%–15% comparable EPS growth for the year.
IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units of common stock on July 30, 2026 under the company’s Director Deferred Compensation Plan. The grant represents $27,280.22 of deferred cash fees, converted at a closing share price of $558.80 per unit. Each unit equals one IDEXX common share, vests immediately, and will be paid in stock after his board service ends or on other preset dates allowed by the plan.
Executive Vice President George Fennell of IDEXX Laboratories reported routine equity compensation activity involving restricted stock units that vested on June 1, 2026. He acquired 639 shares of common stock through the conversion of restricted stock units, while 284 shares were disposed of to cover tax obligations. After these transactions, he directly holds 10,433 shares of common stock, reflecting a net increase in his equity position.
IDXX filed a Form 144 reporting a proposed sale of Common Stock through Goldman Sachs & Co. LLC. The filing lists multiple lots of Restricted Stock Units acquired as compensation on 05/11/2022, 05/11/2023, 05/06/2024, 05/06/2025, and 05/07/2026 with indicated share counts.
IDEXX Laboratories, Inc. reported that shareholders approved key governance changes at the 2026 annual meeting. Amendments to the Amended and Restated Certificate of Incorporation will declassify the Board over three years and move to annual elections for all directors beginning with the 2029 annual meeting.
Shareholders also approved giving investors who own at least 25% of the company’s stock continuously for at least one year the right to require the company to call a special shareholder meeting, subject to conditions in the By-Laws. Three Class II directors were elected through 2029, PricewaterhouseCoopers LLP was ratified as auditor, executive pay received advisory approval, and a separate shareholder proposal on special meeting rights was not approved.
IDEXX Laboratories director Sophie V. Vandebroek reported equity compensation grants in the form of restricted stock units and stock options. She received 234 restricted stock units, each representing one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share. Both the units and options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever comes earlier.